Pharmafile Logo
Pharmafocus logo
Advanced Search

cyramza

Showing 7 posts of 7 posts found.

lilly_entrance_web

FDA advisory committee narrowly backs Eli Lilly’s Cyramza combo for metastatic EGFR+ NSCLC

February 27, 2020
Sales and Marketing Eli Lilly, FDA, cyramza, pharms

Eli Lilly’s Cyramza (ramucirumab) has edged closer to US approval after it scored a recommendation from the FDA’s Oncologic Drugs …

News
lilly_entrance_web

Lilly’s Cyramza approved in US for hepatocellular carcinoma sub-population

May 13, 2019
Sales and Marketing Eli Lilly, FDA, cyramza, hepatocellular carcinoma, pharma

Eli Lilly’s vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyramza (ramucirumab) has received approval in the US as a …

News
lilly_building_with_american_flag_web

Lilly’s Cyramza hits Phase 3 endpoint in first-line metastatic lung cancer treatment

March 13, 2019
Research and Development Cancer, Eli Lilly, cyramza, lung cancer, pharma

Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at …

News
lilly_entrance_web

Cyramza fails to improve overall survival in gastric cancer, Lilly scraps regulatory plans

December 11, 2017
Research and Development, Sales and Marketing Cancer, Eli Lilly, cyramza, gastric cancer, pharma

Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary …

News

Lilly’s Cyramza combo boasts strong results in bladder cancer

September 11, 2017
Research and Development, Sales and Marketing Eli Lilly, bladder cancer, cyramza, immunotherapy, pharma

Eli Lilly has announced new Phase 3 data at the European Society for Medical Oncology 2017 Congress which further add …

News
Cyramza

Lilly to market stomach cancer drug in Europe

December 22, 2014
Sales and Marketing Eli Lilly, Europe, FDA, US, cyramza, ramucirumab, stomach cancer

Eli Lilly has been granted permission by the European Commission to market Cyramza in Europe. Lilly’s Cyramza (ramucirumab) is the …

News
Cyramza image

Lilly’s lung cancer drug sees FDA approval

December 17, 2014
Sales and Marketing BMS, Cancer, FDA, NSCLC, cyramza, docetaxel, lilly, opdivo, ramucirumab

Eli Lilly’s lung cancer drug Cyramza (ramucirumab) has been shown the green light by the US Food and Drug Administration …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025